Vanderbilt researchers have constructed a polygenic risk score for uterine fibroids that will be useful for exploring causes of these benign tumors and identifying novel drug targets and therapies.

Vanderbilt researchers used genetics tools and biobanks with linked electronic health records to explore the associations between statins and noncardiovascular diseases.

Dan Roden, MD, Senior Vice President for Personalized Medicine at Vanderbilt University Medical Center, received the Oscar B. Hunter Career Award in Therapeutics last week at the virtual annual meeting of the American Society for Clinical Pharmacology and Therapeutics.

With the aid of a $75 million, five-year grant renewal, the Electronic Medical Records and Genomics Network (eMERGE) will venture beyond its current focus on monogenic disease to scoring research participants’ relative risk for complex heritable diseases such as cardiovascular disease, chronic kidney disease and type 2 diabetes.

Obesity and two post-operative complications linked with it have associated genetic variants in common, suggesting that obesity may be the culprit.

What do medical biomarkers do on evenings and weekends, when they might be considered off the clock?

In a study in Circulation: Cardiovascular Genetics, Vanderbilt University’s Jonathan Mosley, M.D., Ph.D., and colleagues use genetic correlation to hitch together two unrelated sets of data, one from a longstanding epidemiological cohort and the other from electronic health records.